Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
23 results
D2.308 - Diet quality and intake behaviours among alpha-gal–positive patients at a specialized allergy clinic in Sri Lanka
D2.317 - “Cutaneous Anaphylaxis to Raw Egg White in a Patient with Established Oral Tolerance: Clinical Evidence Supporting the Dual-Allergen-Exposure Hypothesis”
D2.318 - Don`t miss the cannabis-associated food syndrome (CAFS)
D2.303 - The effect of extrusion on the in vivo allergenicity of pistachio and walnut in allergic children
D2.304 - Allergy and Exercise: A Sporting Challenge
D2.305 - Alpha-gal syndrome
D2.306 - From baked cookie to unheated milk: Desensitization in a high-risk cow’s milk protein allergy patient
D2.307 - Parental and Healthcare Professional Experiences of Food Allergen Introduction during Complementary Feeding: A Behavioural Theory–Informed Systematic Review
D2.309 - HAL-MPE1, a novel subcutaneous immunotherapy candidate for peanut allergy. Phase I randomized placebo-controlled study
D2.313 - Scientific Evidence Gaps in FAO/WHO Food Allergen Threshold Guidance: Implications for Risk Assessment and Regulatory Decision-Making
D2.315 - Clinical Characteristics and Diagnostic Challenges in Pediatric Peanut and Tree Nut Allergies: The Impact of Unnecessary Elimination
D2.316 - Novel Homozygous Mutation in CARD11 gene Predisposing To Recurrent Infections and Atopies, and Response to Immunoglobulin therapy
D3.418 - A Phase 1b Study of Lesigercept, a Long-acting High-affinity IgETrap-Fc Fusion Protein: Safety, Tolerability, PK, and PD in Atopic Healthy and Allergic Subjects
D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset
D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study
D3.421 - Real-world Effectiveness and Safety of Lanadelumab Treatment in Patients With Hereditary Angioedema: The 12-Month Interim Analysis of a Polish, Prospective, Multicenter, Observational Study (CHOPIN)
D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes
D3.423 - Lanadelumab treatment is effective and safe in patients with Factor XII associated cold-induced autoinflammatory syndrome: results from an open-label proof-of-concept study
D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria
D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download